October 9, 2006Open Access

Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure

Structured PICO

Does pirfenidone reduce arrhythmogenic atrial remodeling and AF vulnerability in a canine model of heart failure?

Population

Canine model of congestive heart failure (CHF canines)

Intervention

Pirfenidone (PFD)

Outcome

Arrhythmogenic atrial remodeling and atrial fibrillation (AF) vulnerabilitysurrogate

Pirfenidone reduces arrhythmogenic atrial remodeling and AF vulnerability in a canine model of heart failure, suggesting anti-fibrotic therapy may help manage AF.

Abstract

Treatment of CHF canines with PFD results in significantly reduced arrhythmogenic atrial remodeling and AF vulnerability. Pharmacological therapy targeted at the fibrotic substrate itself may play an important role in the management of AF.

KI fragen

Bookmark

View Full Paper